Antibody-drug conjugates (ADCs) represent a groundbreaking advancement in the struggle against cancer. ADCs combine the precision of antibodies with the lethal force of cytotoxic drugs. By delivering these potent agents directly to cancer cells, ADCs maximize treatment efficacy while reducing harm to healthy cells. This directed approach holds sign